Virtual Library

Start Your Search

X. Luo



Author of

  • +

    Epidemiology and outcomes (ID 57)

    • Event: ELCC 2018
    • Type: Poster Discussion session
    • Track:
    • Presentations: 1
    • +

      36PD - New demographic characteristics of lung cancer patients in East Asia? Practice of low-dose spiral computed tomography screening in Shanghai major hospitals (ID 272)

      14:45 - 15:45  |  Presenting Author(s): X. Luo

      • Abstract

      Background:
      We investigated the efficacy of early lung cancer screening with low-dose spiral computed tomography(LDCT) based on the current situation of hospital health service, with integration of superior resources of medical institutions at top levels in Shanghai.

      Methods:
      From November 2012 to November 2017, we screened 6303 (male 2516; female 3787) individuals in three major hospitals in Shanghai City, for early diagnosis of lung cancer with LDCT combined with multidisciplinary comprehensive treatment pattern including minimally invasive surgery, exploring the medical service network covering prevention, diagnosis, treatment, rehabilitation and follow-up.

      Results:
      Screening resulted in a diagnosis of primary lung cancer in 126 participants. The detection rate is 170.9/100,000 among the male participants, and 219.2/100,000 among the female participants (P = 0.180). The detection rate is 207.6/100,000 among the non-smoker participants, and 183.5/100,000 among the smoker participants (P = 0.524). The detection rate is 181.7/100,000 among the participants above 60 years old, and 200.5/100,000 among the participants between the age of 22 and 40 (P = 0.703).

      Conclusions:
      Lung cancer patients in East Asia presents new demographic characteristics: the detection rates among females, non-smokers, and people between the age of 22 and 40 are at least not lower than the traditional-sense high risk population. Females, non-smokers, and people between the age of 22 and 40 should not be excluded from screening with LDCT.

      Clinical trial identification:


      Legal entity responsible for the study:
      Fudan University Shanghai Cancer Center

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.